Search by PDG name  



      Official symbol:  FGFR2
      Full name:  fibroblast growth factor receptor 2
      Location:  10q26.13
      Also known as:  TK25, CFD1, CEK3, CD332, K-SAM, TK14, KGFR, JWS, BEK, ECT1
      Entrez ID:  2263
      Ensembl ID:  ENSG00000066468
      Summary:  The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jan 2009]


  Overall distribution
  Tissue specific distribution

  Overall distribution
  Tissue specific distribution
Gscore (Amp):  0.29  
Gscore (Del):  0.19  
Recurrently amplified in 1 cancer type(s)
Recurrently deleted in 1 cancer type(s)

  Overall distribution
  Tissue specific distribution
Mscore:  0.42  (Driver)
Recurrently mutated in 3 cancer type(s)

  Tissue specific
Total fusion occurrence:  18  (Driver)
Fusions detected in 10 cancer type(s)

  Tissue specific

      Functional class:  Kinase (protein kinase)
      JensenLab PubMed score:  1210.62  (Percentile rank: 96.26%)
      PubTator score:  1106.77  (Percentile rank: 96.84%)
      Target development/druggability level:  TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action.
      Tractability (small molecule):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
      Tractability (antibody):  Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted


Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.